Biopharmaceutical company, Seelos Therapeutics, Inc. (SEEL), Friday announced that it has entered into agreements with institutional investors for the registered direct offering of about 3.4 million shares to raise $4 million and a concurrent private placement priced at-the-market under Nasdaq rules.Following the announcement, shares of Seelos Therapeutics are sliding 6 percent, to $0.98 on the Nasdaq.Under the private placement, the company will offer warrants exercisable for up to 3.4 million shares at $1.05 per share, which will expire 5 years from the date of initial exercise.The company said that it intends to use the proceeds from the offering for product development, pay-off debts and outstanding convertible promissory notes, and for other corporate-related purposes..

生物制药公司Seelos Therapeutics，Inc.（SEEL）周五宣布，它已与机构投资者达成协议，将注册直接发行约340万股股票，以筹集400万美元，并根据纳斯达克规则在市场上同时进行私募。宣布后，Seelos Therapeutics的股价在纳斯达克下跌6%，至0.98美元。根据私募，该公司将以每股1.05美元的价格发行可行权340万股的认股权证，认股权证将自首次行权之日起5年到期。该公司表示，它打算将此次发行的收益用于产品开发、偿还债务和未偿还的可转换本票，以及其他与公司相关的用途。。

The offering is expected to close on or about January 30.Alliance Group Partners is acting as the sole placement agent for the offering. For comments and feedback contact: editorial@rttnews.comBusiness News

此次发行预计将于1月30日左右结束。Alliance Group Partners是此次发行的唯一配售代理。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股